Search for: "ASTRAZENECA LP" Results 81 - 100 of 156
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Oct 2009, 6:05 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: []   Highlights this week included: Seroquel (Quetiapine) – US: CAFC: Sometimes, sins of omission are not inequitable conduct: AstraZeneca Pharmaceuticals LP v. [read post]
25 Aug 2010, 12:37 am by Kelly
Osmotica Pharmaceutical Corp (Patent Docs) Seroquel (Quetiapine) – US: Patent infringement suit filed following Para IV certification: Astrazeneca Pharmaceuticals LP et al. v. [read post]
28 Aug 2009, 8:11 am
Hewlett-Packard Company, AstraZeneca Pharmaceuticals LP, Dow Chemical Company, Advanced Micro Devices, Inc., Dreamworks Animation SKG, et al. [read post]
24 Mar 2012, 1:20 pm by Stewart Walsh
AstraZeneca Pharmaceuticals LP to surprise, and unpleasantly upend the patentee. [read post]
21 Jan 2010, 1:00 am
(Patent Docs) Faslodex (Fulvestrant) - US: Infringement of US Patent following a Paragraph IV certification: AstraZeneca Pharmaceuticals LP et al. v. [read post]
28 Feb 2017, 7:39 am by Dennis Crouch
 The particular claims require “a continuous long term regimen . . . at a dosage up to 1.5 mg/kg/day for not less than 45 days” for treating “an individual with … penile tunical fibrosis …” On anticipation, the court drew a fine-line with its closest case being AstraZeneca LP v. [read post]
10 Nov 2008, 2:07 pm
AstraZeneca Pharmaceuticals LP, the court held that the complexity of having to prove the extent to which there actually was prescribing physician reliance - or none at all - or something in between - required dismissal of a third-party payer suit under Holmes v. [read post]
1 Dec 2010, 12:15 am by Kelly
Navinta LLC (Property, intangible) Pulmicort Respules (Budesonide) – US: Liability for future indirect infringement: AstraZeneca LP v. [read post]
10 Feb 2010, 4:47 pm
(Patent Docs) Colmetec (Olmesartan medoxomil, hydrochlorothiazide) – France: Cour d’appel de Paris say ‘non’ to olmesartan medoxomil and hydrochlorothiazide combination SPC: Daiichi Sankyo Company v INPI (SPC Blog) Crestor (Rosuvastatin) – US: Generic drug makers, Teva, Apotex and others seek to remove AstraZeneca LP as party in Crestor suit (Patent Docs) Differin (Adapalene) – US: Patent infringement complaint following a Paragraph IV… [read post]
15 Dec 2011, 10:17 am by Bexis
AstraZeneca Pharmaceuticals LP, No. 3:11-cv-04001-JAP-TJB, slip op. [read post]
1 Jun 2011, 11:22 am
Ct. 365, 374 (2008); see also AstraZeneca LP v. [read post]
10 Sep 2012, 7:28 pm by FDABlog HPM
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
28 Jul 2010, 12:06 am by Kelly
(Patent Docs) Crestor (Rosuvastatin) – US: Patent infringement complaint following amended ANDA filing: AstraZeneca Pharmaceuticals LP et al. v. [read post]